Article | September 4, 2018

The Big (Bio) Freeze

Source: GE Healthcare Life Sciences
John Morris

Originally published in the Medicine Maker –

The potential of cell therapies has been recognized for some time, but commercialization is a relatively recent endeavor. Cryopreservation is a crucial part of the manufacturing process, because it allows cell therapies to be efficiently stored and transported; however, it is only beneficial if cell viability is maintained. Here, we speak with Asymptote (now part of GE Healthcare Life Sciences) CEO John Morris, who has been freezing cells for over 40 years, to delve into the good, the bad, and the icy aspects of cryopreservation.